N-terminal pro–B-type natriuretic peptide
- Access DeniedUtilizing NT-proBNP for Eligibility and Enrichment in Trials in HFpEF, HFmrEF, and HFrEFGianluigi Savarese, Lars H. Lund, et al.JACC: Heart Failure
- Access DeniedSense and Sensibility of the Use of NT-proBNP for Eligibility in Clinical TrialsAdriaan A. VoorsJACC: Heart Failure
- Access DeniedUtility of Growth Differentiation Factor-15, A Marker of Oxidative Stress and Inflammation, in Chronic Heart FailureInsights From the HF-ACTION StudyAbhinav Sharma, G. Michael Felker, et al.JACC: Heart Failure
- Access DeniedChanges of Natriuretic Peptides Predict Hospital Admissions in Patients With Chronic Heart FailureA Meta-AnalysisGianluigi Savarese, Pasquale Perrone-Filardi, et al.JACC: Heart Failure
Advertisement